Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123955 · ClinicalTrials.gov registry record · Phase 3
PIE II: Pharmacological Intervention in the Elderly II
A Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00123955: Completed Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure, sponsored by Wake Forest University.
NCT00123955 is a Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure that has completed, run by Wake Forest University. The registered enrollment target is 80 participants, below the 673-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00123955, a Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).
Primary Outcome
Peak exercise VO2
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Spironolactone
Study Locations (1)
North Carolina
- Wake Forest University Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00123955 record still lists
NCT00123955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 673-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00123955 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00123955 about?
NCT00123955 is a clinical study titled "PIE II: Pharmacological Intervention in the Elderly II". The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).
What is the current status of trial NCT00123955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2005-04. Estimated completion is 2012-12.
What conditions does trial NCT00123955 study?
This clinical trial studies the following conditions: Heart Failure, Congestive, Diastolic Heart Failure.
What interventions are being tested in trial NCT00123955?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG).
Who is sponsoring clinical trial NCT00123955?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00123955 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00123955's enrollment target sits among peer trials
80 27th of 39 higher than 12 of 39 other Heart Failure, Congestive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
Reversal of Ventricular Remodeling With Toprol-XL
COMPLETED · Phase 3
-
Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery
COMPLETED · Phase 3
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia